Clinical characteristics of human immunodeficiency virus-associated Hodgkin lymphoma patients in Japan

International Journal of Hematology

Volumn 96, Issue 2, 2012, Pages 247-253

  Yotsumoto, Mihoko ^a   Hagiwara, Shotaro ^b   Ajisawa, Atsushi ^c   Tanuma, Junko ^b   Uehira, Tomoko ^d   Nagai, Hirokazu ^e   Fujikawa, Yuko ^f   Maeda, Shunichi ^g   Kitano, Kiyoshi ^h   Arima, Nobuyoshi ⁱ   Uno, Kenji ^j   Iwai, Toshiki ^k   Hongo, Igen ^l   Ota, Yasunori ^m   Fukutake, Katsuyuki ⁿ   Okada, Seiji ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^d OSAKA NATIONAL HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^f Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

^g National Hospital Organization   (Japan)

^h National Hospital Organization Matsumoto Medical Center Matsumoto Hospital   (Japan)

ⁱ Kitano Hospital   (Japan)

^j NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^k KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^l MUSASHINO RED CROSS HOSPITAL   (Japan)

^m TORANOMON HOSPITAL   (Japan)

ⁿ KUMAMOTO UNIVERSITY   (Japan)

more..

Author keywords

ABVD; Antiretroviral therapy; EBV; HIV infection; Hodgkin lymphoma

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER STAGING; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DIGESTIVE SYSTEM PERFORATION; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAPAN; MALE; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84867005931     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1127-5     Document Type: Article

References (38)

1. Noy A. Update on HIV lymphoma. Curr Oncol Rep. 2007;9(5):384-90.
2. Carbone A, Gloghini A, Larocca LM, Antinori A, Falini B, Tirelli U, Dalla-Favera R, Gaidano G. Human immunodeficiency virusassociated Hodgkin's disease derives from post-germinal center B cells. Blood. 1999;93(7):2319-26.
3. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108(12):3786-91.
4. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20(12):1645-54.
5. Dauby N, De Wit S, Delforge M, Necsoi VC, Clumeck N. Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study. J Int AIDS Soc. 2011;14:16.
6. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ, Engels EA. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103(9):753-62.
7. Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink HJ, van Lunzen J, Jaeger H, Stoehr A, Plettenberg A, Wasmuth JC, Rockstroh J, Mosthaf F, Horst HA, Brodt HR. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol. 2004;125(4):455-62.
8. Nguyen ML, Farrell KJ, Gunthel CJ. Non-AIDS-defining malignancies in patients with HIV in the HAART era. Curr Infect Dis Rep. 2010;12(1):46-55.
9. Spina M, Carbone A, Gloghini A, Serraino D, Berretta M, Tirelli U. Hodgkin's disease in patients with HIV infection. Adv Hematol. 2011, pii:402682 [Epub ahead of print].
10. Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, Valencia ME, Abella E, Lopez-Guillermo A, Sureda A, Morgades M, Navarro JT, Esteban H. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica. 2007;92(2):191-8.
11. Spina M, Gabarre J, Rossi G, Fasan M, Schiantarelli C, Nigra E, Mena M, Antinori A, Ammassari A, Talamini R, Vaccher E, di Gennaro G, Tirelli U. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood. 2002;100(6):1984-8.
12. Nagai H, Iwasaki N, Odawara T, Okada S. Actual status of AIDSrelated lymphoma management in Japan. Int J Hematol. 2008;87(4):442-3.
13. The world health organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int. 2000; 50(9):696-702.
14. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. CA: Cancer J Clin. 2011; 61(4):212-36.
15. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21): 1506-14.
16. Serraino D, Boschini A, Carrieri P, Pradier C, Dorrucci M, Dal Maso L, Ballarini P, Pezzotti P, Smacchia C, Pesce A, Ippolito G, Franceschi S, Rezza G. Cancer risk among men with, or at risk of, HIV infection in southern Europe. AIDS. 2000;14(5):553-9.
17. Franceschi S, Dal Maso L, Pezzotti P, Polesel J, Braga C, Piselli P, Serraino D, Tagliabue G, Federico M, Ferretti S, De Lisi V, La Rosa F, Conti E, Budroni M, Vicario G, Piffer S, Pannelli F, Giacomin A, Bellu F, Tumino R, Fusco M, Rezza G. Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998. J Acquir Immune Defic Syndr. 2003;34(1):84-90.
18. Lanoy E, Rosenberg PS, Fily F, Lascaux AS, Martinez V, Partisani M, Poizot-Martin I, Rouveix E, Engels EA, Costagliola D, Goedert JJ. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood. 2011; 118(1):44-9.
19. Dolcetti R, Boiocchi M, Gloghini A, Carbone A. Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. Eur J Cancer. 2001;37(10):1276-87.
20. Ogura M, Itoh K, Kinoshita T, Fukuda H, Takenaka T, Ohtsu T, Kagami Y, Tobinai K, Okamoto M, Asaoku H, Sasaki T, Mikuni C, Hirano M, Chou T, Ohnishi K, Ohno H, Nasu K, Okabe K, Ikeda S, Nakamura S, Hotta T, Shimoyama M. Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305). Int J Hematol. 2010;92(5):713-24.
21. Itoh K, Kinoshita T, Watanabe T, Yoshimura K, Okamoto R, Chou T, Ogura M, Hirano M, Asaoku H, Kurosawa M, Maeda Y, Omachi K, Moriuchi Y, Kasai M, Ohnishi K, Takayama N, Morishima Y, Tobinai K, Kaba H, Yamamoto S, Fukuda H, Kikuchi M, Yoshino T, Matsuno Y, Hotta T, Shimoyama M. Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan. Int J Hematol. 2010;91(3):446-55.
22. Said JW. Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol. 2007;14(3):189-94.
23. Carbone A, Gloghini A, Serraino D, Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS. 2009;4(1):3-10.
24. Dolcetti R, Boiocchi M. Epstein-Barr virus in the pathogenesis of Hodgkin's disease. Biomed Pharmacother. 1998;52(1):13-25.
25. Flavell KJ, Murray PG. Hodgkin's disease and the Epstein-Barr virus. Mol Pathol. 2000;53(5):262-9.
26. Weiss LM, von Wasielewski R, Delsol G, Poppema S, Stein H. Mixed cellularity classical Hodgkin lymphoma. WHO Classification Tumors of Haematopoetic and Lymphoid Tissues, 4th ed.; 2008. p 331.
27. Hishima T, Oyaizu N, Fujii T, Tachikawa N, Ajisawa A, Negishi M, Nakamura T, Iwamoto A, Hayashi Y, Matsubara D, Sasao Y, Kimura S, Kikuchi Y, Teruya K, Yasuoka A, Oka S, Saito K, Mori S, Funata N, Sata T, Katano H. Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy. Microbes Infect. 2006;8(5):1301-7.
28. Stein H, Delsol G, Pileris SA, Weiss LM, Poppema S, Jaffe ES. Classical Hodgkin lymphoma, introduction. WHO Classification Tumors of Haematopoetic and Lymphoid Tissues, 4th Ed.; 2008. p 326.
29. Andrieu JM, Roithmann S, Tourani JM, Levy R, Desablens B, le Maignan C, Gastaut JA, Brice P, Raphael M, Taillan B. Hodgkin's disease during HIV1 infection: the French registry experience. French Registry of HIV-associated Tumors. Ann Oncol. 1993;4(8):635-41.
30. Rubio R. Hodgkin's disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cooperative Study Group of Malignancies Associated with HIV Infection of Madrid. Cancer. 1994;73(9):2400-7.
31. Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani BN, Ratner L. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colonystimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr. 2000;24(5):444-50.
32. Little RF, Yarchoan R, Wilson WH. Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy. Curr Opin Oncol. 2000;12(5):438-44.
33. Keegan TH, Glaser SL, Clarke CA, Gulley ML, Craig FE, Digiuseppe JA, et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol. 2005;23(30):7604-13.
34. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20(3):630-7.
35. Spina M, Re A, Vaccher E, Gabarre J, Tirelli U. High international prognostic score predicts a worse outcome for patients with Hodgkin's disease and HIV infection: results of a prospective study with Stanford V regimen. Ann Oncol. 2003;14(4):655-6.
36. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065-71.
37. Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, Spina M, Manuele R, Vaccher E, Mazzucato M, Abbruzzese L, Ferremi P, Carosi G, Tirelli U, Rossi G. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114(7):1306-13.
38. Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008;14(1):59-66.